Doximity (NYSE:DOCS) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Doximity (NYSE:DOCS) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports.

DOCS has been the subject of a number of other research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Doximity in a research report on Wednesday, December 24th. Wall Street Zen cut Doximity from a “buy” rating to a “hold” rating in a report on Saturday. The Goldman Sachs Group raised shares of Doximity from a “strong sell” rating to a “hold” rating in a research note on Friday. Finally, Barclays upgraded shares of Doximity to a “strong-buy” rating in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Doximity has a consensus rating of “Buy”.

Doximity Price Performance

Shares of DOCS stock opened at $43.85 on Thursday. Doximity has a 1-year low of $43.21 and a 1-year high of $85.21. The stock has a market cap of $8.26 billion, a P/E ratio of 34.80, a P/E/G ratio of 2.03 and a beta of 1.39.

More Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Truist upgraded DOCS from a “hold” to a “strong-buy,” a meaningful bullish signal that can attract buyers and institutional interest. Read More.
• Positive Sentiment: Royal Bank of Canada (RBC) raised its rating to “moderate buy,” highlighting Doximity’s competitive moat and growth prospects — another catalyst supporting the rally. Read More.
• Neutral Sentiment: Goldman Sachs moved DOCS from “strong sell” to “hold” — an improvement in tone but still cautious, which may temper enthusiasm compared with full buy ratings. Read More.
• Neutral Sentiment: Coverage pieces note a mixed picture: RBC praises the growth moat while Goldman flags a potential valuation reset — this frames the stock as a growth story with valuation risk. Read More.
• Neutral Sentiment: Analysts and press are revisiting DOCS after volatile trading and recent AI product updates; these discussions keep attention on execution and monetization of new features. Read More.
• Neutral Sentiment: Multiple comparison and peer-analysis write-ups provide background but are unlikely to move the stock unless they prompt rating changes. Read More.
• Negative Sentiment: Wall Street Zen downgraded DOCS to “hold,” a negative datapoint that could cap near-term upside if echoed by other shops. Read More.

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.